

**PRESS RELEASE**

23 February 2022 16:10:00 CET

## **Senzime applies for FDA approval for a new single-use sensor for children**

**Press release: Uppsala, February 23, 2022. Senzime today announces that they have submitted an application to the US Food and Drug Administration (FDA) for approval of their new single-use sensor for children**

Senzime's digital system for monitoring neuromuscular blockade, TetraGraph, with its single-use sensor TetraSens is approved for the American market since 2019. A flexible small single-use sensor for young children, TetraSens Pediatric, has been developed, and for which the company now has applied for FDA approval.

Studies show that children are at as high risk of complications from the use of paralyzing drugs as adults[1]. The fact that nearly six out of ten patients have residual block when they are awakened after surgery is a risk that can be prevented by monitoring with a precise and quantitative monitor.

Pia Renaudin, CEO at Senzime, says: "*The use of paralyzing drugs in young children is steadily increasing and is now used in a quarter of all pediatric surgeries. Thanks to our innovative R&D team, we are now able to provide a single-use disposable sensor specially developed for children. This sensitive patient group has particularly strong incentives to monitor digitally, objectively, and accurately, which our TetraGraph system enables.*

[1] J Klucka et al, Residual neuromuscular block in paediatric anaesthesia

**For further information, please contact:**

---

Pia Renaudin, CEO of Senzime AB  
Phone: +46 (0) 70-813 34 17, email: [pia.renaudin@senzime.com](mailto:pia.renaudin@senzime.com)

### **About Senzime**

---

Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared monitoring systems for patients undergoing anesthesia. Senzime's employees worldwide are committed to the vision of a world without anesthesia related complications. Six out of ten patients that wake up after surgery are not fully muscle recovered and therefore at risk having critical respiratory complications. The TetraGraph system helps anesthesia providers improve patient care and reduce healthcare costs by digitally and continuously measure the degree of neuromuscular blockade under and after surgery. Senzime operates in the world's leading markets targeting a market opportunity valued in excess of SEK 15 billion per year. The company's shares are listed on Nasdaq Stockholms main market (ticker SEZI). [www.senzime.com](http://www.senzime.com)

## Attachments

---

Senzime applies for FDA approval for a new single-use sensor for children